Apoptosis Market By Mechanism 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Apoptosis Market
Apoptosis Market Analysis: By Mechanism (Molecular Pathways, Caspase Activators and Inhibitors, Protease/Proteasome Inhibitors, Bcl-2 Modulators, p53 Modulators and Others); By Drug Class and By Type of Disease Treatment – With Forecast (2016-2021)
Report Code : HCR 0135
Published: 26 February, 2016   No. of pages: 149

  • Report Description
  • Table of Contents
  • Customization Options
Programmed self destruction of damaged or abnormal cells is termed as apoptosis. When cells in multicellular organism are no longer required, intracellular destruction of the cells begins. However, excessive and insufficient apoptotic processes have been known to be associated with several diseases. While excessive apoptosis is attributed to atrophy, an insuffienct apoptosis can result in an uncontrolled proliferation of unwanted cells and can result in cancer. There are several other diseases such as neurodegenerative diseases such as Alzeihmer’s, Huntinton’s and ALS and other autoimmune diseases that are stem from either a failure of apoptosis in elimination of harmful cells or unwanted activation of apoptosis that can result in destruction of important cells. Several drugs are available in the market and those currently being research exhibit apoptosis modulating properties. 

Rising number of cancer detected patients across the globe is one of the main drivers for the apoptosis market. Research and development efforts by companies as well as universities, sometimes in collaboration, is another factor augmenting the growth of this market. Lack of awareness is one factor that can potentially restrain the growth of this market.

An important section on patent analysis is included in this report that explores some of the most influential patents and potential indications for apoptosis modulation.

Apoptosis Market

The Apoptosis market can be segmented on the basis of mechanism as:
  • Bcl-2 Modulators
  • Caspase Activators and Inhibitors
  • p53 Modulators
  • Protease/Proteasome Inhibitors
  • Molecular Pathways 
  • Others.

The Apoptosis market has also been segmented on the basis of the class of drugs as:
  • Direct apoptogens
  • First generation indirect apoptogens
  • second generation indirect apoptogens 
  • reagents and kits

One of the main application of apoptosis is for the treatment of cancer. 
In terms of type of disease treatment, the Apoptosis market has been segmented across the following diseases:
  • Cancer
  • Neurodegenerative diseases
  • Cardiovascular Diseases 
  • Others

North America currently accounts for the largest share of the global apoptosis market with Europe coming a close second. The market in emerging and developing economies in APAC and South America are expected to grow at higher rates comparatively till the end of the forecast period. 

The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

Following are just a few of the companies that are operating in the Apoptosis market: 
  • Pfizer
  • Novartis
  • Amgen Inc
  • Abbott Laboratories 
  • Aegera Therapeutics Inc
1. Apoptosis– Market Overview
2. Executive Summary 
3. Apoptosis– Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4.  Apoptosis– Market Forces
   4.1. Market Drivers 
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Apoptosis Market 
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Apoptosis Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Apoptosis Market– By Mechanism:
   6.1. Bcl-2 Modulators
   6.2. Caspase Activators and Inhibitors
   6.3. p53 Modulators
   6.4. Molecular Pathways
   6.5. Protease/Proteasome Inhibitors
   6.6. Others
7. Apoptosis Market– By Drug Class:
   7.1. Direct Apoptogens
   7.2. First Generation Indirect Apoptogens
   7.3. Second Generation Indirect Apoptogens
   7.4. Reagents and Kits
8. Apoptosis Market– By Type of Disease Treatment:  
   8.1. Neurodegenerative Diseases
   8.2. Cardiovascular Diseases
   8.3. Cancer
   8.4. Others
9. Apoptosis Market– By Geography:
   9.1. Introduction
   9.2. Global Study
   9.3. Americas
      9.3.1. North America 
      9.3.2. Brazil
      9.3.3. Argentina
      9.3.4. Others 
   9.4. Europe
      9.4.1. U.K.
      9.4.2. France
      9.4.3. Germany
      9.4.4. Others
   9.5. APAC
      9.5.1. China
      9.5.2. Japan
      9.5.3. India
      9.5.4. Others
   9.6. ROW
10. Apoptosis Market– Market Entropy
   10.1. New Product Launches
   10.2. M&As, Collaborations, JVs and Partnerships
11. Company Profiles 
   11.1. Abbott Laboratories Inc.
   11.2. Zentaris GmbH
   11.3. Novartis
   11.4. AbGenomics International Inc.
   11.5. Aegera Therapeutics Inc.
   11.6. ApopLogic Pharmaceuticals Inc.
   11.7. Infinity Pharmaceuticals Inc.
   11.8. Genta Inc.
   11.9. Anavex Life Sciences Corporation
   11.10. Chromo Therapeutics Limited
   11.11. Amgen Inc.
   11.12. EntreMed Inc.
   11.13. Pfizer Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix
   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports